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Introduction
More than 90% of the genome of human is transcribed 
as non-coding RNAs (ncRNAs). This subject suggests 
that ncRNAs as functional RNA molecules might involve 
in regulation of gene expression at the transcriptional 
and post-transcriptional levels in human cells (Ponting 
and Belgard, 2010; Siegel et al., 2014; Kurozumi et al., 
2017).  Short ncRNAs (eg microRNAs or miRNAs) and 
long ncRNAs (or lncRNA) are two broad categories 
of ncRNAs and in recent years have been revealed to 
have key functions in various biological processes (i.e., 
growth, differentiation) especially in cancers (Kurozumi 
et al., 2017; Monteleone and Lutz, 2017). lncRNAs are a 
various class of ncRNAs with more than 200 nucleotides 
in length (Bartonicek et al., 2016). They can be located 
within introns, between genes or be transcribed as natural 
antisense of coding genes and play prominent roles 
in development of various normal cells and diseases 
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progression (Derrien et al., 2012; Kung et al., 2013). 
Aberrant expression and dysregulation of lncRNAs such 
as PCGEM1, SPRY4-IT1, PANDAR, and ROR has 
been shown in malignant cells (Srikantan et al., 2000; 
Jiang et al., 2017; Liu et al., 2017; Xu et al., 2018). 
According to the position and transcription direction, 
lncRNAs are categorized into subgroups including 
antisense, overlapping, intergenic, intronic, bidirectional, 
and processed (Bartonicek et al., 2016). Given that 
understanding of involved non-coding RNAs in cancer 
pathogenesis could contribute to better treatment of cancer 
(Xu et al., 2017).
Long intergenic non-protein-coding RNA 1296 
(LINC01296) is mapped to 14q11.2 and plays an 
important role in several types of cancers. LINC01296 
has been suggested acts as a tumor-promoting in different 
malignancies including gastric cancer(Qin et al., 2018), 
prostate cancer (Wu et al., 2017), colorectal cancer 
(Qiu and Yan, 2015). Up regulation of LINC01296 in 
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gastric cancer cells and cell lines resulted to aggravate 
GC development using the miR-122/MMP-9 axis (Qin 
et al., 2018). It has been shown LINC01296 silencing 
could suppress proliferation of prostate cancer cell and 
its invasion. Moreover, its expression could be introduced 
as a biomarker for survival analysis in prostate cancer 
patients (Wu et al., 2017). Overexpression LINC01296 
was associated with poor prognosis of patients with 
colorectal cancer (Qiu and Yan, 2015). Up regulation 
of LINC01296 in pancreatic ductal adenocarcinoma 
tissues and non-small cell lung cancer was related to cell 
growth and progression, clinical characteristics and poor 
prognosis (e.g. lymph node metastasis and increasing in 
TNM stage)(Xu et al., 2019; Yuan et al., 2019).
In this study, we hypothesized that LINC01296 might 
influence the survival of patients with various cancers. 
There is no meta-analysis has been implemented to assess 
the correlation between LINC01296 and the survival of 




This article was reported according to recommended 
guidelines Cochrane library for systematic reviews; the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) (Moher et al., 2009a).
Search strategy
Identification of relevant articles for this study 
performed by searches of PubMed, EMBASE, Web 
of Science, and Scopus between December 2000 and 
28 December 2018. The electronic search terms were 
[LINC01296 and Cancer (with special MeSH terms for 
PubMed and Emtree terms for Embase)]. Manual search 
was performed in reference list and citations of included 
studies as well as related websites. Two authors (PKH 
and FS) were cooperated in all stages. Differences were 
discussed until agreement was reached. It was necessary 
to contact study author for several times. Country was not 
limited in this search strategy.
Inclusion and exclusion criteria
We included studies that meet the subsequent criteria: 
(1) case control and cohort studies that evaluate the 
correlation between the clinicopathological parameters 
and LINC01296 in patients with cancer; (2) cancer should 
be diagnosed according to histopathological evaluation; 
(3) None of the patients had undergone radiotherapy or 
chemotherapy treatment before surgery (4) full articles 
published in English. In this study we excluded: (1) the 
studies that solely were related to cancer or LINC01296; 
(2) animal study; (3) the study was a review or abstract; 
(4) Studies whose information was inaccessible.
Data Extraction and Risk of Bias
Two authors (PKH and FS) independently reviewed 
by title, abstract and full text and extracted the data 
from identified eligible studies. Probable discrepancies 
between two independent experts were resolved under 
the supervision of the main investigator (YM). The 
following data were extracted: the first author’s name 
first author; year of publication; the patient gender; site of 
cancer and tumor type; tumor stage; sample size and co-
variants; outcome; type of treatment interval; experimental 
techniques used. Finally, we using the Newcastle-Ottawa 
Scale (NOS) assessed the methodological quality of 
included studies (Wells, 2001).
Statistical analysis
Binomial data were evaluated by the odds ratio (OR) 
as the rapid statistic. The correlation between LINC01296 
and survival of cancer was evaluated by combining the 
HR with its corresponding 95% CI. The heterogeneity 
of studies examined by I2 statistic and the chi-squared 
based Q-statistic test. The fixed effect models were 
used to estimate the pooled effect sizes across studies. 
Determination of all the P-values was performed using 
a 2-sided test. Software for all statistical analyses was 
STATA software version 13.
Ethics statement 
Consent to participate was unnecessary.
Results
Study characteristics
Figure 1 show the PRISMA flow diagram (Moher 
et al., 2009b) of study identification of relevant studies. 
Fifty-seven studies were found in the preliminary search. 
After a comprehensive evaluation comprises remove 
of duplicates, exclusion based on title or abstract and 
exclusion based on some reasons such as inaccessibility 
to their data, finally, 9 studies with 720 patients with 
cancer were included in this meta-analysis. Pancreatic 
ductal adenocarcinoma (PDAC), non-small cell lung 
cancer, Esophageal squamous cell carcinoma (ESCC), 
Cholangiocarcinoma, breast cancer, urothelial carcinoma 
of the bladder, prostate cancer, gastric cancer was studied 
in the original studies. The characteristics of the included 
studies have been shown in Table 1. The data of Overall 
Survival (OS) extracted from Only 5 studies.
Results of the meta-analysis
Table 2 shows the associations between the 
clinicopathological criteria and the LINC01296 expression. 
No significant association was identified between the 
LINC01296 expression and gender (OR = 1.10, 95% 
CI = 0.78-1.53) (Figure 2 and Table 2). Moreover, the 
LINC01296 expression was not related to the patients age 
(OR = 1.31, 95% CI =0.96-1.8) (Table 2). Conversely, 
the expression of LINC01296 showed a significant 
positive association with TNM stage (OR = 2.67, 95% 
CI = 1.83-3.88) (Table 2), tumor stage (OR= 2.22, 95% 
CI= 1.34-3.66) (Table 2 and Figure 3) and lymph node 
metastasis (invasion) (OR = 3.07, 95% CI = 2.23-4.21) 
(Figure 4). Additionally, a shorter OS (overall survival) in 
patients was significantly associated with the expression 
of this RNA (HR = 3.95, 95% CI = 2.65-5.25) and lymph 
node metastasis (HR = 2.39, 95% CI =1.16-3.63) (Table 2). 
The OS did not show significant association with gender 
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Discussion
Recently, several studies have demonstrated abnormal 
expression of LINC01296 has been associated with several 
malignancies (Jiang et al., 2018). Therefore, based on 
information provided by several studies, we performed the 
first meta-analysis to assess the correlation between the 
LINC01296 expression and prognosis based on patients 
clinicopathological parameters in cancers. The results of 
our meta-analysis demonstrated that the expression of 
LINC01296 was significantly related with lymph node 
metastasis, TNM stage and Tumor stage. Moreover, 
(HR = 0.83, 95% CI = -0.63-2.30) and tumor stage (HR= 
2.66, 95% CI= -0.22-5.54) (Table 2).
Meta Regression 
Meta regression was used to explore the sources 
of heterogeneity among studies, including age and 
gender. The results of this this analysis showed that the 
associations are not related to age (B= -0.00043, P=0.345, 
95% CI -0.007, 0.0010) and gender (B= 0.0380, P=0.478, 
95% CI -0.046, 0.022).
Publication Bias Assessment
The results of Egger’s test show no significant bias 
occurred in the publication of the results (Egger’s test = 
1.01 SE: 0.221, P = 0.443).
Figure 1. PRISMA Flow Diagram of Study Identification
Figure 2. Forest Plot Illustrating the Association between the LINC01296 Expression and Gender of Patients
Farzane Saeidi et al
Asian Pacific Journal of Cancer Prevention, Vol 212192
prognostic factors univariate analysis for OS in this study, 
showed a significant association between OS of patients 
with cancer and the LINC01296 expression and lymph 
node metastasis. Since, patients with high expression 
of LINC01296 compared with those had a low level of 
the expression, had a poor prognosis, the expression of 
LINC01296 might be considered as a potential biomarker 
in patients with cancer.
In a study, Anna Katharina Seitz et al.,(Seitz et al., 
2017) identified aberrant expression of lncRNAs in 
8 normal and 72 breast cancer samples using RNA-
sequencing. Among identified 89 lncRNAs that were 
significantly dysregulated, in vitro LINC01296 silencing 
reduced cell viability and migration. Moreover, they 
demonstrated that both LINC00958 and LINC01296 
localized to both the nucleus and the cytoplasm and 
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Female)











Yuan, Q., et al. 2018 47 / 38 Pancreatic ductal adenocarcinoma NA 85 OS 53 / 32 T1-4 7
Xu, L., et al. 2018 26 / 14 NSCLC I-IV 40 OS* 20 / 20 NA 7
Wang, B., et al. 2018 134 / 87 Esophageal squamous cell carcinoma I-IV 221 OS 83 / 138 NA 7
Wang, L., et al. 2017 60 / 18 Esophageal squamous cell carcinoma I-IV 78 OS* 27 / 51 T1-4 7
Zhang, D., et al. 2017 32 / 25 Cholangiocarcinoma I-IV 57 OS* 28 / 29 NA 7
Jiang, M., et al. 2018 55 (Female) Breast cancer I-III 55 OS 36 / 19 NA 7
Wang, X., et al. 2019 30 / 24 Urothelial carcinoma of the bladder NA 54 OS 18 / 36 NA 7
Wu, J., et al. 2017 73 (Male) Prostate cancer NA 70 OS 38 / 32 T2-4 7
Qin, Q.H., et al. 2017 33 / 27 Gastric cancer I-III 60 OS* 48 / 12 T1-3 7
Table 1. Features of the Included Studies
OS, overall survival; OS*, no data of OS could be extracted; NOS, Newcastle-Ottawa Scale; NA, not available; NSCLC, Non‐small cell lung cancer
Figure 3. Forest Plot Illustrating the Association between the LINC01296 Expression and Tumor Stage
Correlation test Heterogeneity
OR 95% CI P-value I2 (%) P-value
Gender 1.09 0.78-1.53 0.592 0 0.956
Age 1.31 0.96-1.8 0.086 0 0.556
TNM stage 2.67 1.83-3.88 0 0 0.914
Tumor stage 2.22 1.34-3.66 0.002 0 0.401
Lymph node metastasis 3.07 2.23-4.21 0 45.6 0.065
Univariate analysis Heterogeneity
HR 95% CI P-value I2 (%) P-value
Gender 0.83 -2.93 0.265 0 0.998
Tumor stage 2.66 -5.76 0.071 65.7 0.054
Lymph node metastasis 2.39 1.16-3.63 0 0 0.801
LINC01296 expression (High vs Low) 3.95 2.65-5.25 0 26.1 0.248
Table 2. The Association between LINC01296 and Clinicopathological Criteria AND Univariate Analysis of Prognostic 
Factors for Overall Survival
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knock-down of them altered the expression of genes 
related to cell death/survival and cellular growth/
proliferation pathways. According to these findings, they 
suggested that LINC01296 act as oncogenes by stimulating 
proliferation and the metastatic process in breast cancer 
cells (Seitz et al., 2017). XIN YU et al., assessed the 
levels of LINC01296 expression in osteosarcoma cells 
in comparison to normal cells (Yu et al., 2018). Their 
findings revealed, the up regulation of LINC01296 was 
closely associated with the poor survival of osteosarcoma 
subjects. LINC01296 acts as an oncogenic factor which is 
able to increase the proliferation, invasion, and migration 
of osteosarcoma cells. Moreover, the expression of 
Cyclin D1 was positively correlated with the LINC01296 
expression in osteosarcoma cells so that LINC01296 
knockdown could lead to down regulation of  cyclin D1 
(Yu et al., 2018). It has been shown that Overexpression 
of LINC01296 is one of very important players in the 
progression of CRC(Qiu and Yan, 2015). In a Bing Liu et 
al., (Liu et al., 2018), shown that LINC01296 correlated 
with poor clinical prognosis in patients and the malignancy 
of CRC cell lines. Alteration of the LINC01296 expression 
impresses proliferation and metastasis of CRC cell 
and cause in vitro chemoresistance to 5-fluorouracil 
(5-FU). LINC01296 as a miR-26a direct target through 
LINC01296/miR-26a/GALNT3 axis encourage CRC 
malignancy using regulating O-glycosylated MUC1 
by PI3K/AKT pathway. Upregulation of LINC01296 
stimulates the in vivo tumorigenesis, liver metastasis 
and chemoresistance of CRC cell lines(Liu et al., 2018). 
Upregulation of  LINC01296 was significantly seen in 
some another cancers such as gastric cancer, prostate 
cancer, urothelial carcinoma of the bladder and esophageal 
squamous cell carcinoma that in all of them correlated 
with lymph node metastasis, advanced TNM stage, and 
shorter overall survival(Wu et al., 2017; Qin et al., 2018; 
Wang et al., 2018; Wang et al., 2019).
LINC01296 knockdown using siRNAs could be 
related to inducing of cell apoptosis. LINC01296 could 
Figure 4. Forest Plot Illustrating the Association between the LINC01296 Expression and Lymph Node Metastasis
suppress cell apoptosis via targeting the Bcl-2/caspase-3 
pathway(Yuan et al., 2019). Bcl-2 is known as a central 
regulator of cell life and death and caspase-3 acts as 
an effector caspase which has a crucial role in cell 
apoptosis process (Evan and Littlewood, 1998; Mantena 
et al., 2006). In an epithelial-mesenchymal transition 
(EMT) process, a polarized epithelial cell by multiple 
biochemical changes accepts a mesenchymal cell 
phenotype. Gained features of this phenotype comprise 
enhanced capability of migratory, invasiveness, higher 
apoptosis resistance, and significantly increased ECM 
components production(Kalluri and Neilson, 2003). The 
loss of epithelial proteins such as E-cadherin and higher 
expression of nonepithelial markers such as N-cadherin 
and Vimentin are of the important features of EMT(Dong 
et al., 2012). Knockdown of INC01296 by reversing Snail-
mediated EMT decrease the capacities of invasiveness 
and migration. Taken together,  these findings, the axis of 
LINC01296/Snail/ E-cadherin may have an important role 
in facilitating metastatic properties of pancreatic ductal 
adenocarcinoma(Yuan et al., 2019).
At the end of, some limitations of this meta-analysis 
comprise of following: 1) only 5 studies provide the 
survival data and only 1 study could provide the disease-
free survival data. 2) The sample size collected for overall 
survival analysis in this study was small that this subject 
does not provide statistical power to make a significant 
assessment.3) Also, implementation of subgroup analysis 
in one specific cancer or based on the ethnicity due to 
inadequate data was not possible. 4) Because of not 
doing an in vitro experiment, therefore, more studies for 
results confirmation of this meta-analysis are needed. In 
conclusion, this meta-analysis suggests that LINC01296 
may be a diagnostic biomarker for shorter OS and 
metastasis.
In conclusion, cancer is one of very important 
public health problems which is associated with high 
rate mortality and mobility in patients with this disease. 
Finding, designing and developing new diagnostic 
platforms could contribute to increase survival rate of 
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cancer patients. In this regards, a variety of biomarkers 
have been introduced by pre-clinical studies. Taken 
together, the results of this meta-analysis suggest that 
the expression of LINC01296 might be considered as a 
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